The Scalpel and the Pen—Equal Partners

According to one encyclopedic source, a periodical differs from a newspaper in that, among other things, it purports to present views and opinions of its authors and editors instead of recounting current news. The obvious flaws in that definition notwithstanding, it does have a healthy ring of truth to it where the Bulletin is concerned.

True, the Bulletin does print what might be termed “information-as-news”, but in many respects it is a journal of opinion—and learned opinion at that. Scientific contributions are, when all is said and done, the products of extrapolated opinion, and quite often blatantly state that certain observations have led the author or authors to a certain opinion. And our non-scientific articles are more often than not expressions of opinion in themselves.

Hopefully, the opinions expressed in the Bulletin’s pages have a meaning and a value beyond that of Shakespeare’s “brief shadow”, and however much they may strut and fret it is equally to be hoped that the brief candle of their passing will fire the touchstone of opinion in others.

Today, more than ever, the medical community and society as a whole must learn not only to express opinion but to do so productively. It is a time when sane, reasoned, and even forceful comments on the Canadian condition are urgently needed.

It is a time when, as the economy shudders and confusion replaces hope, the too often unheard voices of reasonable men and women must be heard. Possibly it is a time when communities should stop looking for direction and turn toward supplying the seeds of that direction from within themselves.

Physicians, it has often been said, suffer from the isolation of their singular expertise. Their contribution to society and the demands of the profession have tended to block their peripheral vision and to have limited their awareness of broad concepts. While the Bulletin doesn’t hold this to be true, the fact remains that the potential for leadership and direction in many professions and highly skilled employment categories has, either through inertia or through imposed limitations, not been realized. Sadly, the smothered potential syndrome can, and possibly has, become a habit.

But, as we are prone to tell our patients, it is a habit which can be broken, and unless we are committed to the terminal implications of indifference it is a habit which must be broken.

Opinion — intelligent opinion — can help. A synthesis of many opinions can help even more. That’s what the Bulletin is here for. Come to think of it, that’s what you’re here for.
Thomas J. McKeough, M.D., president of The Medical Society of Nova Scotia, has had a distinguished career as a physician, a popular representative in Provincial Government, and as a Cabinet Minister and leader. Born in Sydney Mines, where he still makes his home, Dr. McKeough received his post-secondary education at St. Francis Xavier University, Dalhousie University and the Ottawa University Medical School. He has served as a member of the Sydney School Board and, following his election to the Provincial Legislature some fifteen years ago, successively assumed responsibility for the portfolios of Municipal Affairs, Labour, Trade and Industry, Finance and Economics and, once again, Labour. Currently, he is the official opposition's finance critic. He is married to Marie-Paul Mantha of Ottawa and has six children: Michel, Louise, Daniel, Brian Paul, Marcel and Denise.

J.W. Reid, M.D.
in the treatment of diffuse cerebral insufficiency

PRESCRIBING INFORMATION

DOSAGE

- for 4 weeks
- for 6 weeks

Afterward the daily dose can, if warranted, be reduced to 2 tablets.

Patients should be convinced of the necessity and importance of taking their medication regularly every day, preferably with their meals and at bedtime. The difference between success and failure is often directly related to the way the patient follows the dosage schedule.

Composition — Tablets: Each 1 mg tablet contains the methanesulfonates of dihydroergocornine, dihydroergocristine and dihydroergokryptine in equal proportions. Ampoules: Each 1 ml ampoule contains 0.3 mg Hydergine consisting of the methanesulfonates of dihydroergocornine, dihydroergocristine and dihydroergokryptine in equal proportions.

Side Effects — Hydergine is usually well tolerated even in larger doses. Side effects are few and very slight. In addition to nasal stuffiness, there may be nausea, gastric pressure, anorexia, and headache, especially in patients with autonomic lability. In such cases, it is advisable to reduce the dose or administer it during or after meals.

Contraindications — Severe bradycardia and severe hypotension.

Supply: Bottles of 100 and 500 tablets; Boxes of 6 and 100 ampoules.

Full prescribing information is available upon request.

SANDOZ
DORVAL, QUEBEC

GUEST HOUSES... HOTELS... MOTELS...
PRIVATE CHALETS... APARTMENTS...
SKI DORMS...

1200 accommodations within 12 miles

Package deals including meals, ski lessons and lift tickets. Let us know the kind of accommodation you wish and rest assured of our full cooperation for a pleasant stay.

CANADIAN TOY TESTING COUNCIL
The C.M.A. Council on Community Health reviewed pamphlets and a booklet published by the Canadian Toy Testing Council and believed that these would be useful in doctors' waiting rooms. Up to 25 copies of each pamphlet can be supplied free of charge to those interested. Requests should be sent to:

Mrs. MacFarlane
Canadian Toy Testing Council
P.O. Box 6014
Station "J"
Ottawa, Ontario K2A 1T1
Telephone: (613) 731-2822
INTRODUCTION

The antibiotic, Fucidin, manufactured in Copenhagen, Denmark, developed from the fungus Fusidium coccineum was isolated in 1953 by the Japanese mycologist, K. Tubaki, from a sample of monkey dung. Initial tests revealed that Fusidium strains were devoid of penicillinase activity. Subsequent testing showed them to possess anti-staphylococcal activity and this led to the production of fusidic acid. Although Fucidin has been extensively used in Continental Europe, Britain and elsewhere, it is not yet licensed for clinical use in Canada. Of necessity, our trials have been limited by availability and cost.

In accordance with the provisions of Section C 08.010 of the Food and Drug Act and Regulations of the Government of Canada, we have obtained sufficient Fucidin for the staphylococcal osteomyelitis presenting unusually different management problems in orthopaedic surgery and infection control.

Although Fucidin exhibits potent anti-staphylococcal activity, it has been emphasized that in order to avoid the development of resistance, Fucidin should be administered in combination with other antibiotics, to derive its maximum effect.

Case I. P.M.F., age 37 leaped from the second floor of a burning building. He was admitted to hospital with a severe fracture of his pelvis; diastasis of the symphysis pubis and left sacro-ilial joint; comminuted fracture of the upper shaft of the left femur; an undisplaced fracture of the right os calcis and a minor vertebral injury.

He was treated by the insertion of a Steinman pin through the tibial tuberosity and placed in pelvic traction. Subsequently, open reduction and internal fixation with a blade plate were performed over a period of six weeks. During this interval he developed pneumonia as a complication of smoke inhalation, and infection of the surgical wound site of the left thigh accompanied by osteomyelitis of the leftibia due to Staphylococcus pyogenes. He received a course of cloxacillin (Penbritin) and cephalothin (Keflin), but without response. On 17th December, Fucidin was administered by intravenous catheter through the right subclavian vein and he received 500 mg/q8h/5 days.

Response to therapy was good, wound discharge ceased and patient was able to start physiotherapy.

Case II. L.E.L., age 55, fractured his left humerus in 1968, after a pit accident, and was treated by open reduction and internal fixation. Treatment failed, and following several unsuccessful attempts at fixation, the condition resulted in non-union. Subsequently, a plating procedure at Toronto proved successful and union of the fracture resulted. Later, he developed osteomyelitis with a chronic draining sinus of the left arm, for which he received a lengthy course of antibiotic medication.

Organisms found to be present were Staph. pyogenes resistant to penicillin, Pseudomonas aeruginosa resistant to gentamicin plus several other antibiotics, and Alkaligenes species. These bacteria presented a difficult combination to overcome and it was decided first to eliminate Ps. aeruginosa with BB-K8 (A mikacin, Bristol) IV/500 mg/q8h/5 days, and q6h for a further 5 days. Secondly, to eliminate Staph. pyogenes with a course of Fucidin IV by the subclavian route, administering 500 mg/8h/10 days.

The patient made a good recovery, the wound became dry and no growth on culture was obtainable.

Case III. G. Dew, Age 19. One and half years prior to admission, he was hit by a multiple wheel trailer tractor, which ran over his left foot. All the tarsal and metatarsal bones were crushed. He was treated at Burlington, Ont. and remained in hospital for some 3 months and successfully averted the amputation of his foot. Seen later at the Victoria General Hospital in Halifax, he showed osteomyelitis of the second metatarsal bone with moderate discharge. X-ray findings indicated an area of lucency, together with suggestion of avascular fragments or sequestra at the base of the second cuneiform bone.

Infection was due to a pure growth of Staph. pyogenes. Due to the multiplicity of antibiotics which the patient had previously received in hospital, it was not surprising to find that the strain of Staph. pyogenes isolated, was resistant to penicillin, tetracycline, streptomycin, erythromycin, chloramphenicol, lincomycin, kanamycin, polymyxin B and carbenicillin.

The following course of antibiotic therapy was employed. Cephalothin IV/1 gm/q6h/10 days; BB-K8 (Amikacin) IV/500 mg/q8h/10 days. This was followed by a second
course of antibiotics consisting of Fucidin IV by the subclavian route 500 mg/q8h/3 days, followed by oral therapy with Fucidin PO/250 mg/q8h/4 days, and clindamycin PO/150 mg/q8h/14 days. At the conclusion of treatment, the sinus had closed and purulent discharge had ceased. He still had some tenderness in his left foot, but is able to walk and hopes to return to his occupation as a truck driver.

Case IV. D.C.A., age 28, had suffered for many years from the adverse consequences of multiple birth defects.

At 6 months of age, she received remedial surgery for spina bifida and later a fragment of bone was removed from her right buttock area. Subsequently, she was provided with an ileal bladder. This was followed by a below right knee amputation and a tendon transplantation.

Ureteral and urethral obstruction also received appropriate surgical attention, and a silt urethra was effected to enhance drainage.

On admission to hospital in September 1974, she presented with a decubitus ulcer on the dorsum of her right foot with probable early involvement of infection in the underlying bone. Organisms grown on culture were Staphylococcus pyogenes, Staphylococcus epidermidis, anaerobic Micrococcus, Streptococcus, Enterococcus, Proteus mirabilis, Pseudomonas aeruginosa and Candida albicans. The patient was allergic to penicillin and in view of the numerous antibiotics she had previously received, she was placed on the following course of therapy in an effort to eliminate each organism seriatim. Gentamicin IV/40 mg/q8h/12 days: tetracycline IV/350 mg/q12h/10 days followed by tobramycin (Neobcin, Lilly) IV/40 mg/q8h/14 days. Following use of these antibiotics, the growth of Staph.epidermidis, Proteus mirabilis and Pseudomonas aeruginosa ceased. Candida albicans and Staph.pyogenes still persisted and for these, she received 5-fluorocytosine (Ancobon — Roche) PO/500 mg/q8h/10 days. This was followed by Fucidin PO/250 mg/q8h/14 days, after which no further growth of Staph.pyogenes occurred. The ulcer had now healed sufficiently to enable a skin graft to be performed. The immediate prognosis was fair, but the long term function of the foot as a weight bearing area, warranted a guarded prognosis.

Case V. N.M. age 64, a diabetic, sustained a subtrochanteric fracture of the left hip in May 1974. This was treated surgically by internal fixation with a Richards screw and plate. Subsequently, the wound became infected and he developed osteomyelitis with a discharging sinus. Later, debridement of the wound, irrigation and suction, removal of the screw and plate and application of a spica cast were performed. The patient received an intensive course of antibiotic therapy and after a second debridement of the area in December 1974, healing was sufficiently advanced to permit closure and discharge home in April 1975. The infecting organism throughout his illness was Staph.pyogenes, resistant to penicillin, ampicillin and cloxacillin, and he received the following antibiotics — ampicillin, cloxacillin, clindamycin and vancomycin, but without response. On October 17, 1974, he was started on Fucidin PO/500 mg/q8h/10 days, followed by diethanolamide fusidate IV via the subclavian vein 500 mg/q6h/6 days — ampicillin IV/500 mg/q6h was given simultaneously. During the combined administration of Fucidin and ampicillin, there was marked improvement in the patient’s condition. The hip sinus was also packed with repeated applications of Fucidin Gel.2,3,4

Case VI. C. S., age 59. Fell and fractured his left hip. He was treated by internal fixation with a Richards screw and plate. Four months later, X-ray examination revealed that the pin had become dislodged from the head of the femur. This was removed at a subsequent operation where a revision and Girdlestone arthroplasty were performed. Further treatment consisted of traction for 7 weeks plus suction drainage. Bacteriological examination of wound discharge showed the presence of Enterobacter, B.proteus mirabilis; Pseudomonas sp; Acromobacter anitarum and Staphylococcus epidemidis.

Antibiotic therapy consisted of Fucidin IV/50mg/q8h/9 days. Fucidin oral capsules 250 mg/q8h/10 days employed in combination with Gentamicin IV/80 mg/q8h/5 days, and Dalacin C IV/150 mg/q8h/17 days.

The patient made a slow recovery and is now able to walk with the aid of crutches.

Case VII. This man, age 27, sustained an accidental self inflicted gun shot wound of his right shoulder, at point blank range, whilst duck hunting in a boat. He was treated by removal of the lead shot with surgical debridement of the wound, plus such repairs to traumatized tissues as were possible to effect at the time. For the next 8 years, he experienced intermittent pain, with breakdown of the injured tissues, accompanied by draining sinuses.

On admission to the V.G.H. x-ray examination revealed multiple foreign bodies surrounding the joint area, destruction of the shoulder articulation, partial destruction of the humeral head and its separation from the glenoid cavity. An old fracture through the neck of the humerus was also detected, with bony sequestrum in the area of the humeral head.

At operation, the draining sinus was excised from its base as it extended deep into the shoulder joint; also removed was some cartridge wadding, together with some fragments of fabric of a shirt or hunting jacket which he happened to be wearing 8 years ago. Having removed all visible foreign bodies, the humerus, acromion and glenoid were curretted and the joint cavity irrigated with bacitracin saline solution. The base of the sinus tract which had been directed through the shoulder joint was left open, but the fibrous tissue overlying its anteriorly was closed, as well as the deep tissues, to obliterate the dead space.

Bacteriological culture of wound discharge revealed the presence of Bacillus bacteroides and Staph.pyogenes. The following combination of antibiotics was selected for specific treatment.

Fucidin IV by subclavian route/500 mg/q8h/10 days. Dalacin C IV/150 mg/q6h/10 days.

Patient made a good recovery and he expressed his desire to go on another hunting trip.
DISCUSSION

The following description of Fucidin has been provided by the Manufacturers: "Fucidin (sodium fusidate B.P.) developed in 1962 by Leo research, is the most potent of the three steroid antibiotics (the other two being helvolic acid and cephalosporin P). It is chemically and biologically unique, being unrelated to any other antibiotic used in medical practice. The structure of Fucidin is fundamentally different from that of the hormonal steroids and there has been ample evidence during the past five years to show that Fucidin is devoid of demonstrable endocrine effects; indeed, no pattern of toxicity to any system has emerged during this period.

While Fucidin is active against a range of Gram-positive bacteria and Neisseria, interest has centred on its bactericidal effect on most strains of staphylococci, including those which are resistant to other antibiotics. It is widely distributed in the body and of particular significance are the concentrations found in relatively avascular tissues such as chronically inflamed bone, inflamed connective tissue and burn crusts. Fucidin possesses ability to penetrate relatively avascular sites such as chronic inflamed bone. Likewise its ability to penetrate dead sequestra to produce concentrations greatly exceeding that requisite for inhibition of staphylococcal growth may render it a valuable agent in the therapy of Staphylococal osteomyelitis.

After a daily dose of 3.0 grams per day for 6 days, the Fucidin concentrations in bone were found to vary from 3.4 to 4.8 J.tg/g. The presence of the drug in sequestra was of special interest. After a daily dose of 3 Gm for 7 days followed by reduced dosage for as long as 6 months, has been recommended.

In selected cases diethanolamidefusidate can be given by the IV route, preferably into a wide bore vein with good blood supply. A total dose of 4 G per 24 hours should not be exceeded. Possible adverse effects observed have been jaundice, venospasm and thrombophlebitis. Mild gastro-intestinal disturbance and occasional rashes have also been noted to occur. There is no evidence that its steroid nucleus may cause metabolic effects.

Stewart (1964) reported that Fucidin concentrations of 4-8 µg/ml were detected in bone. Deodhar et al. (1972) treated cases of osteo and rheumatoid arthritis with 0.75 or 1.5 gm of sodium fusidate daily for 3 to 7 days and observed concentrations of 7 µg/ml in aspirated synovial fluid. Fucidin is widely distributed throughout the body and is slowly excreted so that after doses of 3 G/day (40 mg/Kg) Saggars et al. (1966) found that the plasma concentration rose to 45-200 µg/ml. Fucidin has been shown to be active against many penicillinase producing strains of Staphylococci, but the in vitro development of resistant mutants to Fucidin has been observed to occur. It has therefore been recommended by Waterworth (1963) and Garrod, et al. (1973) that Fucidin should be administered in combination with other antibiotics. We have followed this advice and have done so including combination with a newer antibiotic BB-K8 (Amikacin).

The objective of this publication has been to report the use of this antibiotic in Canada, and to add that we consider that it may be a valuable adjunct to therapy in the cases studied. Due to restrictions imposed on access to larger supplies of the drug, we are unable to draw conclusions further than our limited data would permit.

SUMMARY

Seven cases of osteomyelitis presenting management problems in orthopaedic surgery and infection control, have been treated with Fucidin, employing the intravenous, oral and topical preparations, in combination with other antibiotics.

The results have been sufficiently encouraging to warrant more extensive trial of what appears to be a valuable antistaphylococcal antibiotic possessing properties which make it of special interest to the orthopaedic surgeon.
INSURANCE PROGRAM

SOCIETY MEMBERS

EMPLOYEES OF SOCIETY MEMBERS

THE MEDICAL SOCIETY OF NOVA SCOTIA

THE NOVA SCOTIA DIVISION

OF

CANADIAN MEDICAL ASSOCIATION

For information on how your Society's insurance plans may be of benefit to you and your employees...

PLEASE TURN PAGE
MEDICAL SOCIETY INSURANCE PROGRAM

INSURANCE:
- Life (Assignable & Convertible)
- Long Term Disability & Partial Disability
- Business Expense
- Accidental Death & Dismemberment

LIFE INSURANCE: (Maximum Available $200,000.00)

<table>
<thead>
<tr>
<th>Age</th>
<th>Under 31</th>
<th>31-35</th>
<th>36-40</th>
<th>41-45</th>
<th>46-50</th>
<th>51-55</th>
<th>56-60</th>
<th>61-75</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual Premium per $25,000.00</td>
<td>$60.36</td>
<td>$70.80</td>
<td>$76.56</td>
<td>$98.04</td>
<td>$126.96</td>
<td>$199.68</td>
<td>$272.04</td>
<td>$421.92</td>
</tr>
<tr>
<td>Special Student Rates Available for $25,000.00</td>
<td>Under 31 $38.04 per year</td>
<td>31 &amp; Over $41.88 per year</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

LONG TERM DISABILITY: (Lifetime for accident, age 65 for sickness)
(Maximum available $2,000.00 monthly, all sources)

ELIMINATION PERIODS

<table>
<thead>
<tr>
<th>Age</th>
<th>15 Days</th>
<th>30 Days</th>
<th>60 Days</th>
<th>90 Days</th>
<th>180 Days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Under 31</td>
<td>$22.44</td>
<td>$18.72</td>
<td>$17.40</td>
<td>$16.08</td>
<td>$14.28</td>
</tr>
<tr>
<td>31-35</td>
<td>$23.88</td>
<td>$20.04</td>
<td>$18.60</td>
<td>$17.16</td>
<td>$15.24</td>
</tr>
<tr>
<td>36-40</td>
<td>$28.08</td>
<td>$23.54</td>
<td>$21.84</td>
<td>$20.16</td>
<td>$17.76</td>
</tr>
<tr>
<td>41-45</td>
<td>$35.52</td>
<td>$29.76</td>
<td>$27.60</td>
<td>$25.32</td>
<td>$22.56</td>
</tr>
<tr>
<td>46-50</td>
<td>$43.08</td>
<td>$36.00</td>
<td>$33.36</td>
<td>$30.72</td>
<td>$27.24</td>
</tr>
<tr>
<td>51-55</td>
<td>$50.88</td>
<td>$42.60</td>
<td>$39.48</td>
<td>$36.36</td>
<td>$32.16</td>
</tr>
<tr>
<td>56-60</td>
<td>$60.00</td>
<td>$50.16</td>
<td>$46.44</td>
<td>$42.72</td>
<td>$37.80</td>
</tr>
<tr>
<td>61-75</td>
<td>$69.84</td>
<td>$58.32</td>
<td>$54.00</td>
<td>$49.68</td>
<td>$43.92</td>
</tr>
</tbody>
</table>

INTERNES MAY APPLY FOR $750.00 AND RESIDENTS FOR $1,000.00, REGARDLESS OF INCOME

PARTIAL DISABILITY: (Maximum available $2,000.00 per month)
(Maximum six months coverage following full disability)

ANNUAL PREMIUM PER $50.00 MONTH COVERAGE:

| Coverage For 12 Months | $8.16 | $6.48 | $8.00 | $5.52 |

BUSINESS EXPENSE: (Maximum available $2,000.00)

<table>
<thead>
<tr>
<th>Age</th>
<th>Coverage For 12 Months</th>
<th>Coverage For 18 Months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Under 50</td>
<td>$18.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>51-60</td>
<td>$27.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>61-70</td>
<td>$36.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>

ACCIDENTAL DEATH & DISMEMBERMENT: (Maximum available $100,000.00)
(In conjunction with Long Term Disability)

$9.60 per year for each $10,000.00 unit of principal sum.
Local Anaesthetic Drugs
Some Pharmacology And Physiology

PART I

J. A. Smith,* M. D., F. R. C. P. (C),
Halifax, N. S.

Perhaps no class of drugs is as frequently administered directly by physicians and dentists as local anaesthetics. Considering the relatively low therapeutic ratio, surprisingly few adverse reactions apparently occur. In two articles, it is hoped to review some of the more important aspects of these drugs, including their toxicity, and the physiology relating to them.

NERVE CONDUCTION

In the resting state, the nerve fiber is like a cocked gun. Due to the sodium pump in the nerve membrane, an imbalance of ionic concentration exists between the interior and the exterior of the nerve fiber. Outside (interstitially) the [Na+] is 150 mEq; inside it is 15 mEq. Outside the [K+] is 5.5 mEq; inside it is 150 mEq. The sodium pump actively pumps Na+ from inside the nerve fiber, and the nerve membrane is impervious to its passive return. This results in a deficit of positive ions inside the fiber, and K+, assisted by the sodium pump, flows in to correct the electrical imbalance. The resulting high interior [K+] however, is somewhat diminished because of passive outward leakage of K+ down the concentration gradient. This results in a net deficit electronegative (-50 to -70 mV) with relation to the outside. This is called the resting membrane potential.

Impulses generated in nerve cells inactivate the sodium pump, and make the membrane permeable to Na+ and K+ ions, which now move rapidly down their concentration gradients. As the ions move, a sudden reversal of polarity occurs at a critical point, the firing threshold, and the interior becomes electropositive (+20 to +40 mV) in relation to the outside. That part of the neuron is now said to be depolarized and is refractory to further conduction until the sodium pump reestablishes the normal ion concentrations and polarity.

This “front” of electrical activity with the resulting internal electropositivity causes similar ion flows in the adjacent segment of neuron, causing electrical reversal, membrane permeability, and depolarization. Thus the wave of depolarization or “impulse” is conducted along a neuron.

BLOCKING IMPULSE CONDUCTION

Blocking the conduction of an impulse in a nerve can be done in several ways. However, methods such as cutting the nerve and applying a physical toxin are not reversible, and methods such as altering the [K+] and [Na+] inside or outside the nerve are not possible. Many substances have been found to have the property of blocking impulse conduction in nerves in a completely reversible and non-toxic manner. The best of these are used as local anaesthetics. Their side effects are tolerably infrequent and usually not severe.

These agents, when present in sufficient concentration at the nerve membrane, prevent depolarization from occurring. They apparently act at certain binding sites on the nerve membrane, displacing Ca2+ which is necessary for normal conduction. This prevents the attainment of the firing threshold and blocks the passage of Na+ and K+ down their concentration gradients, i.e., the whole sequence of depolarization.

RELATIONSHIP OF STRUCTURE TO ACTIVITY

Local anaesthetics have two keys components, one lipophilic and the other hydrophilic. They are connected by a chain of four or five carbon atoms. The lipophilic (aromatic) portion, a derivative of either para-amino benzoic acid or aniline, imparts fat soluble properties to the molecule. The hydrophilic portion, almost always a tertiary amine, imparts water solubility.

Various alterations in the structure are accompanied by alterations in potency, duration of action, solubility, and toxicity.

When the lipophilic radical is a derivative of para-amino benzoic acid, it is connected to the intermediate chain via its hydroxyl (OH) tail forming an ester linkage.
Examples of ester linked local anaesthetics are procaine (Novocaine) and tetracaine (Pontocaine). When the lipophilic radical is an aniline derivative, the linkage to the intermediate chain is via an amino group.

Examples of amide linked local anaesthetics are lidocaine (Xylocaine), mepivicaine (Carbocaine), bupivicaine (Marcaine) and prilocaine (Citanest).

**SYSTEMIC EFFECTS OF LOCAL ANAESTHETICS**

**Cardiovascular System**

All local anaesthetics, except cocaine and perhaps mepivicaine, cause dilation of peripheral blood vessels, due to a direct smooth muscle relaxant effect. They facilitate their own absorption and shorten their duration of action. Circulating local anaesthetics also tend to lower peripheral resistance and the blood pressure.

Relative to the heart, local anaesthetics increase the refractory period, raise the ventricular excitation threshold, prolong the intracardiac conduction time, and lengthen the QRS interval. They also reduce the contractile force in a dose related fashion and reduce cardiac output. However, these effects are seldom evident or significant in usual clinical concentrations.

All local anaesthetics possess antiarrhythmic properties. Procaine is not useful because of its rapid destruction in the plasma. Lidocaine is the most useful and has the widest safety margin. It is used intravenously in an initial dose of 1-2 mg/kg in 30 seconds followed at a rate of 1 mg per minute. The half life of its cardiac effects is said to be 20 minutes.

Lidocaine is effective in about 85% of ventricular arrhythmias, but only in about 15% of supraventricular arrhythmias. Procainamide (Pronestyl) is more effective in the latter.

The mechanism of action is still somewhat obscure. In nontoxic concentrations, measurable electrophysiological changes are minimal. It alters or abolishes the phase of slow depolarization during diastole in Purkinje fibers, and shortens the duration of action potential and the effective refractory period. Conduction times are not consistently altered. One might assume that local anaesthetics alter the phase of slow depolarization in other parts of the heart, thus tending to prevent ectopic stimuli from occurring, and when they do occur, tending to prevent their conduction.

THE NOVA SCOTIA MEDICAL BULLETIN 10 FEBRUARY, 1976
Toxic doses exaggerate the effects of slowing conduction, reducing the force of contraction in the heart, reducing peripheral resistance and can produce cardiovascular collapse.

**Central Nervous System**

Local anaesthetics have interesting and apparently paradoxical effects on the central nervous system. Low doses are anticonvulsant; medium doses are sedative, high doses are convulsant, and extremely high doses are depressant. The mechanisms of these various effects are unclear, but the basic cause is probably a depressant effect.

As an anticonvulsant, approximately equal seizure protection is provided by 2mg/kg of lidocaine, 4mg/kg of mepivicaine, and 10mg/kg of pentobarbital. Lidocaine has the greatest therapeutic dose range between seizure protection and seizure induction. Lidocaine is effective in interrupting grand mal seizures in man, and is especially effective in cases of status epilepticus. The dose is 2-3mg/kg at a rate of 40-50mg/minute. A small dose of a barbiturate will greatly enhance the anticonvulsant property of local anaesthetics.

Slightly higher doses usually cause sedation, but can cause euphoria, excitement, amnesia, vertigo, anxiety, palpitations, tinnitus, diplopia, paraesthesias, and flushing. Some of these may appear as premonitory signs of impending severe toxicity.

The most dramatic and dangerous complication of local anaesthetic use is the generalized convulsion. It is seen when the blood level exceeds a certain minimum. Experimental evidence indicates that the initial disturbance is in the limbic system of subcortical and temporal nuclei, probably in the amygdala. If the dose of local anaesthetic is sufficient, the initial hyperactivity is not confined to the amygdala, but spreads to the cortex causing generalized seizures.

The disturbance in the amygdala has been shown to be very similar to that of temporal lobe or psychomotor epilepsy. The mechanism of action is probably not a stimulating effect by the local anaesthetic, but rather the depression of some small cells whose normal function is the inhibition of activity in the amygdala. Diazepam has been found to be quite effective in cases of temporal lobe epilepsy and has been found to be the most effective treatment for convulsions in the newborn, caused by transplacental mepivicaine.

Experimentally, a high plasma CO₂ tension enables seizures to be induced with lesser amounts of local anaesthetic. Conversely, a low CO₂ tension enables higher doses of local anaesthetics to be tolerated before seizures are induced. Thus, hyperventilation is indicated in subconvulsant or convulsant states. Seizures themselves are not thought to be directly harmful to the brain. Brain damage is a consequence of associated cardiovascular and respiratory depression resulting in hypotension and hypoxia. The arterial O₂ tension, for instance, regularly falls to 20mm/Hg in untreated grand mal seizures.

The doses of local anaesthetics given intravenously or for regional block result in blood levels which have no effect on axonal conduction in other peripheral nerves or in the spinal cord. They have, however, an inhibiting effect on poly- and mono-synaptic reflexes. There is also evidence that lidocaine, at least, has a depressant effect on a synaptic transmission in the brain stem. As evidence of this, intravenous lidocaine is a strong cough suppressant.

**Other Organ Systems**

Local anaesthetics have been shown to have ganglionic blocking activity, neuromuscular blocking activity, anticholinergic, antihistaminic, and antibacterial activity. None of these are reported when they are used alone. They can become significant when administered concurrently with other drugs which may compliment these effects. Local anaesthetics have been shown to depress the rate and force of contraction of uterine muscle, but appear not to do so in normal clinical dosages.

In the next article will be covered the uptake, metabolism, excretion, and hypersensitivity, and toxicity related to local anaesthetics.

---

**ONE POINT OF VIEW**

The economics of health is a curious discipline, somewhat in the tradition of the theology of indulgences which flourished before Luther. You can count what the friars collect, you can look at the temples they build, you can take part in the liturgies they indulge in, but you can only guess what the traffic in amnesties for purgatory does to the soul after death. Models developed to account for the rising willingness of tax-payers to foot rising medical bills provide similar scholastic guesswork about the new world-spanning church of medicine.

Medical Nemesis
The Expropriation of Health, 1975
Ivan Illich
Application for Participation in - THE CANADIAN MEDICAL ASSOCIATION RETIREMENT SAVINGS PLAN

I hereby apply to the Trustee for participation in the Canadian Medical Association Retirement Savings Plan, ("the Plan") the provisions of which are familiar to me. I understand that the Plan is sponsored by The Canadian Medical Association in conjunction with The National Life Assurance Company of Canada and The Royal Trust Company. I request that the instruments evidencing the terms of the Plan be registered as a Retirement Savings Plan under the Income Tax Act (Canada). I understand that as a consequence of such registration payments out of the Plan can only be made in the form of a life-contingent annuity or as a death benefit and that such payments to me or to my beneficiaries, executors or legal representatives will be subject to tax under the provisions of the Income Tax Act (Canada). However, I understand that I may deregister my Plan by amendment but in so doing I will be required to include in computing my income for a taxation year all amounts received by me in that year from my deregistered Plan.

I request that future contributions be apportioned to The National Life Assurance Company of Canada, Group Savings Policy No. G.A. 495 and to the Canadian Medical Association Investment Fund managed by The Royal Trust Company in the percentages as specified on the form below. I understand that this percentage allocation may subsequently be varied by written notice in accordance with the provisions of the Plan.

I understand that all premiums (contributions) made in the year or within 60 days after the end of the year are receivable for income tax purposes subject to the amount of premium deductible as specified under the provisions of the Income Tax Act (Canada).

I undertake, upon request, to provide proof of age satisfactory to the issuer in respect of any annuity contracts provided to me as a benefit under these plans.

I hereby appoint The Canadian Medical Association to act as my Agent in the negotiation of contracts and agreements to carry out the provisions of the Plan.

If I am domiciled in the province of Quebec, I further request that my application be approved in accordance with the provisions of Order In Council No. 280 of the province of Quebec, with all consequences this involves.

Return to - THE CANADIAN MEDICAL ASSOCIATION - 1867 Alta Vista Dr., Ottawa, Ontario K1G 0G8

In order to take advantage of 1974 tax relief your contribution herewith must be in lump sum. Future contributions may be made monthly, quarterly, or annually and allocated to the Common Stock or Annuity Fund in the proportions you designate on each contribution date.

A statement of account recording your current and accumulated contributions will be mailed to you at the month end after your contribution is received.

C.M.A.R.S.P. APPLICATION for office use only

NAME ___________________________ (Family Name) ___________________________ (Given Names)
ADDRESS ___________________________ No. & Street ___________________________ Apt. No.
City ___________________________ Province ___________________________
Postal Code ___________________________
DATE OF BIRTH ___________________________ Day Month Year ___________________________
Sex ___________________________
Language Choice ___________________________
□ Male ___________________________
□ French ___________________________
□ Female ___________________________
□ English ___________________________
SOCIAL INSURANCE NO. ___________________________

BENEFICIARY ___________________________ (Family Name) ___________________________ (Given Names)
RELATIONSHIP OF BENEFICIARY TO YOU ___________________________

NOTE: In the event of your death, your benefits in the Insured Annuity Fund will accrue to the beneficiary named and may be used to purchase one of a variety of annuities. Your benefits in the Common Stock Fund are considered as part of your estate and disposition should be by your will. There are tax advantages in bequeathing these assets specifically to your spouse.

ALLOCATION OF CONTRIBUTIONS

Percentage of contributions to be invested in the Common Stock Fund (C.M.A.I.F.- Fund "A") ___%_

Percentage of contributions to be invested in the Short Term Deposit Fund ___%_

Percentage of contributions to be invested in the Insured Annuity Fund ___%_

TOTAL 100%_

(WITNESS) ___________________________

(SIGNATURE OF APPLICANT) ___________________________

DATE ___________________________
PleaSe READ REVERSE SIDE ___________________________

If you would like to receive information on the automatic contribution system - Pre-Authorized Payments Plan, please check this box □

If this application is being submitted by a C.M.A. member's spouse, please print your own name in full and indicate your own C.M.A.R.S.P. account number if you have an account.

NAME ___________________________

C.M.A.R.S.P. No. 11- ___________________________
WITH CMARSP AND CMARHOSP
The Canadian Medical Association Retirement Savings Plan
&
The Canadian Medical Association Registered Home Ownership Savings Plan

YOU SAVE ON TAXES AND COMMISSIONS

These two CMA sponsored tax deferred savings programs provide a number of options for members to save money and reduce taxes. You pay no sales commissions or other “loading” charges, but you still receive professional management of the money you invest.

IF YOU ACT BEFORE FEBRUARY 28
YOU CAN REDUCE YOUR 1975 TAXABLE INCOME BY $5,000*

A Reminder to Current Members

If you are one of the 13,000 plus CMA members enrolled in the Canadian Medical Association Retirement Savings Plan (CMARSP) this is a timely reminder to be sure to take full advantage of the deductions allowed from taxable income, even if you have to borrow to complete your 1975 contributions to CMARSP. Interest on money borrowed for contributions to a registered retirement savings plan is fully deductible from taxable income.

Your contributions can be allocated to the Common Stock Fund, the Short Term Deposit Fund or to the Insured Annuity Fund in whatever portions you wish. You may also open a CMARSP account for your spouse and thus take advantage of income splitting for lower taxes now and in the future. For more information contact CMA in Ottawa or your Provincial Branch.

CMARHOSP Offers Additional Tax Saving Opportunities

If you did not own a home in 1975 you can reduce your 1975 taxable income by an additional $1000 by investing in the Canadian Medical Association Registered Home Ownership Savings Plan. Funds accumulated in this Plan can be used to purchase a new home or furnishings for it, or they can be transferred to a registered retirement savings plan.

*Maximum allowable annual contributions: CMARSP $4000 – CMARHOSP $1000

IT IS NOT TOO LATE TO ENROLL
IN EITHER OR BOTH THESE PLANS

APPLICATION FORMS ARE PROVIDED FOR YOUR CONVENIENCE

If you have yet to take advantage of the tax savings and sound investment management available to CMARSP and CMARHOSP members, now is the time to do so. For more details call or write Mr. R.P. Bannerman, Vice-President of MD Management at CMA House, Ottawa (613) 731-9331. Because of the limited time left to obtain 1975 tax relief through these plans, applications forms are provided on the preceding and following pages. Please fill in completely, including Social Insurance Number which is required to issue tax receipts. Please forward your personal cheque (separate cheques for each plan) together with your completed application form or forms to:

MD Management Limited
1867 Alta Vista Drive
I hereby apply to The Royal Trust Company for a Canadian Medical Association Registered Home Ownership Savings Plan ("the Plan") in accordance with the terms of the Plan. I request that my plan be registered with the applicable taxation authorities.

I hereby declare:
1. that I am at least 18 years of age and of the age of majority in accordance with the applicable laws;
2. that I am a resident of Canada;
3. that I have not previously been a beneficiary of a registered home ownership savings plan;
4. that I do not own or have an interest in a partnership that owns, in either case whether jointly or otherwise, real property in Canada, any portion of which was used as a dwelling place by any individual at any time in the calendar year up to the date of this application.

I hereby authorize the Canadian Medical Association to act as my agent for the general administration and promotion of the Canadian Medical Association Home Ownership Savings Plan and I elect that my contributions shall be invested in the Canadian Medical Association Investment Fund in the following proportions.

(a) ________% to be invested in "A" units; (Common Stock Fund)
(b) ________% to be invested in "B" units; (Fixed Income Fund)

I agree that this investment direction shall apply to future contributions to the Plan unless and until by notification in writing I advise the Plan that subsequent contributions shall be invested in different proportions.
Local Anaesthetic Drugs
Some Pharmacology And Physiology

PART II

J.A. Smith,* M.D., F.R.C.P.(C).
Halifax, N.S.

PREAMBLE

In the previous article, we reviewed the physiology of nerve conduction and how it may be blocked, the pharmacological nature of local anaesthetics, and some structure activity relationships.

We will now discuss the fate of local anaesthetics in the body, toxicity, and hypersensitivity.

UPTAKE AND DISTRIBUTION OF LOCAL ANAESTHETICS

Uptake of Local Anaesthetics

Local anaesthetics are absorbed from tissues in relation to the local vascularity and the vasodilating effect and dosage of the particular local anaesthetic. Resulting blood levels depend not only on the above, but also on the rate of inactivation and/or removal from the plasma.

Absorption can be slowed by the addition of adrenalin. This promotes local vasoconstriction and prolongs the duration of action. The optimum concentration of adrenalin is 1:200,000. Higher concentrations do not significantly improve vasoconstriction and increase the incidence of side effects from possible intravascular injection.

Except cocaine, all local anaesthetics are readily absorbed through intact mucous membranes — the rate depending on the vascularity. Blood levels following application of local anaesthetics to the laryngeal mucous membrane and mucous membranes that are inflamed may approach those attained through intravenous injection.

Distribution of Local Anaesthetics

Initially local anaesthetics in the blood are distributed disproportionately to the highly perfused organs. Redistribution begins immediately, as binding occurs with plasma proteins (chiefly albumin) and affinities of certain local anaesthetics for certain tissues make themselves felt. Bupivacaine (Marcaine) for example, is the most highly bound to plasma proteins. Lidocaine (Xylocaine) and mepivicaine (Carbocaine) have the greatest affinities for fatty tissue, liver, kidney, and brain. The destruction of procaine in the plasma is rapid, so high blood levels are unlikely.

Local anaesthetics also distribute themselves between the plasma and erythrocytes in specific ratios, varying for each agent. The ratios for each are proportional to the protein binding capacity. The degree of protein binding is related to the duration of action; bupivacaine being the longest acting local anaesthetic currently in use. Its presence in the blood is prolonged by being highly protein bound.

Organ Barriers

Local anaesthetics cross all organ barriers with relative ease. Blood-brain equilibrium after intravenous injection occurs in ten minutes. The placental barrier is crossed with ease. Lidocaine appears in the fetal blood in two to three minutes following maternal injection, and remains measurable for 45 minutes. Passage to the fetus is related to the degree of protein binding. Bupivacaine, being the most highly bound to protein in the maternal blood, will exhibit the lowest fetal — maternal ratio of blood levels.

The barrier presented by the dura of the spinal cord is more formidable, but there is evidence that local anaesthetics cross in some quantities, both via the nerve root sheaths following peridural injection, and via the blood stream. Following peridural injection, peak maternal blood levels occur in 20-40 minutes, in the fetus in 30-45 minutes. The lidocaine levels in infants born within 15 minutes of peridural injection average 50% that of the mother. Procaine is metabolized by the placenta and fetal blood levels seldom approach 50% of the maternal levels. Bupivacaine levels in the fetus average 20-30% those of the mother.

All local anaesthetics are not as highly bound to fetal protein as to maternal. It follows then that a dose that is partitioned between protein and plasma to yield non-toxic levels in the mother could produce toxic levels in the fetus.

Prilocaine (Citanest) crosses the placenta easily and fetal levels may approach or even exceed those of the mother. It is apparently poorly metabolized by the fetus, in contrast to lidocaine and mepivicaine.

Accumulation of Local Anaesthetics

Accumulation of local anaesthetics in the plasma and tissues depends on the rate of administration, absorption, inactivation, and excretion. The half life of lidocaine, for example, is about 90 minutes, and 45% of an injected dose is still unchanged in the body after two hours. Hence, accumulation can occur and the plasma level may be expected to rise with consecutive doses which exceed the removal rate.

* Lecturer, Department of Anaesthesia, Victoria General Hospital, Halifax, N.S.
A safe rate of administration seems to be 1 mg/min, but doses as high as 3.5 mg/min for five days have been reported without adverse effects. The maximum single dose of lidocaine into the tissues is 4-5 mg/kg.

The maximum single dose of bupivacaine is 150 mg. Not more than 400 mg in 24 hours should be given.

THE FATE OF LOCAL ANAESTHETICS IN THE BODY

The disposal of local anaesthetics by the body is related to the chemical structure. Those with an ester linkage (e.g. procaine, tetracaine) are destroyed chiefly in the plasma by pseudocholinesterase. Procaine is rapidly hydrolysed to form para-amine benzoic acid and diethylaminoethanol. The former is excreted largely by the kidneys, the latter is further metabolized. Tetracaine is hydrolysed much more slowly. Since procaine and succinylcholine are both destroyed by pseudocholinesterase, prolonged effects of either may be expected when one is given in the presence of the other. No cases are reported, but people with absent, low, or atypical pseudocholinesterase might be expected to have a prolonged duration of action from procaine and other ester-linked local anaesthetics.

The amide-linked local anaesthetics (lidoceaine, mepivicaine, bupivacaine, prilocaine) are metabolized chiefly in the liver by enzymatic hydrolysis. Prilocaine is also metabolized to some extent in the kidneys. Several pathways of metabolism in the liver have been identified.

The stability and resistance of amide-linked local anaesthetics to non-enzymatic hydrolysis may be appreciated when one realizes that lidocaine, for example, is stable in the presence of strong acids and alkalis, and it can be boiled and autoclaved repeatedly without significant loss of potency.

Cocaine is eliminated almost entirely unchanged by the kidneys and about 10% of injected lidocaine appears in the urine unchanged. There is evidence that acidification of the urine aids excretion. There is also excretion of small amounts of local anaesthetics in the bile.

ADVERSE EFFECTS OF LOCAL ANAESTHETICS

We must distinguish between hypersensitivity and toxicity. Toxicity is related to the concentration in the blood. The higher it is and the longer it remains high, the more likely a toxic effect. Hypersensitivity is true allergy.

Hypersensitivity

Allergy is uncommon and is apparently limited to the ester linked local anaesthetics, especially procaine. Dermatitis, edema, urticaria, bronchospasm have all been reported. Cross allergies may exist between procaine and structurally related chlorprocaine, tetracaine, and procainamide.

A complicating factor is that the preservative methylparaben, usually added to local anaesthetic solutions, has also been shown to be allergenic. The parabens are also derivatives of para-amino benzoic acid (a component of all ester linked local anaesthetics) and are widely distributed in nature. So one can see not only that direct allergy to methylparaben is possible, but also a cross allergy to any ester linked compound, and all without apparent prior sensitization.

Contrary to popular belief, there is no documented case of allergy to the amide-linked local anaesthetics. Most occasional reports have not been properly investigated and could have been due to the preservative methylparaben or a reaction to sudden absorption of adrenaline, which is a common constituent of local anaesthetic solutions. De Jong states "hypersensitivity to lidocaine and related compounds is so rare as to be virtually negligible". It must be realized that anyone allergic to procaine could exhibit a cross allergy to amide-linked compounds containing methylparaben. For people with such possible allergies, the preparations of lidocaine and marcaine marked for epidural, and lidocaine for intravenous use should be chosen, since they do not contain methylparaben. Even with these agents, however, it is wise to do skin testing prior to use.

Cytotoxicity

There is no cyto- or histotoxicity caused by the usual doses and concentration of local anaesthetics. Reports of tissue reaction at injection sites are usually found to be due to infection or hematoma. In days past, tissue reaction could be caused by metallic ions (Cu, Ni, Zn) mobilized from metal syringes or medicine cups by the extra acidity imparted to the local anaesthetic by the adrenaline antioxidant sodium bisulphite.

Central Nervous System Toxicity

When excessive levels of local anaesthetic are reached in the blood, central nervous system toxicity occur with generalized convulsions. These have an abrupt onset, a violent character and have potentially serious consequences, apparently from associated hypoxia from respiratory and circulatory impairment.

The prevention of seizures is of prime importance although the rapid absorption of injected local anaesthetics is, at times, unavoidable. One can do no more than avoid direct intravenous injection, use the least amount of agent possible (milligrams, not milliliters), use a vasoconstrictor when possible, and have an intravenous running. It is difficult to administer oxygen, start an intravenous, and give drugs to a convulsing patient.

Some possible premonitory signs of an impending seizure have been mentioned (euphoria, excitement, anxiety, palpitations, tinnitus, diplopia, paraesthesias, and flushing). At the first sign of these stop administering the local anaesthetic, give oxygen and ask the patient to hyperventilate, which will raise the seizure threshold. Premedication with diazepam may be beneficial as a preventive measure.
Treatment of Seizures
Seizures are usually brief due to rapid redistribution and removal of the local anaesthetic from the circulation. Proper resuscitation apparatus, oxygen and ambu bag, drugs, barbiturates, vasopressors and muscle relaxants, should always be available when local anaesthetics are administered.

Patients should be protected from self-injury, hypoxic or hypotensive injury by hyperventilating them with oxygen and using vasopressors. It may be necessary to use short-acting muscle relaxants to make adequate oxygenation possible.

Barbiturates remain the mainstay of therapy, but as little as possible should be given as there is evidence that their depressant effects are additive to those of local anaesthetics.

Cardiovascular Toxicity
Most investigators agree that cardiovascular collapse is always secondary to central nervous system and respiratory center depression. Treatment with oxygen, intravenous fluid, and vasopressors is indicated for cardio-vascular collapse.

Local Anaesthetics in Epileptics
There is no evidence that epileptics have greater sensitivity to local anaesthetics. Paradoxically, local anaesthetics may be used to terminate epileptic seizures.

Prilocaine
A unique kind of toxicity can occur with prilocaine. Excessive doses (more than 600 mg) can lead to the appearance of a dusky cyanosis. This is due to the formation of methemoglobin as a result of a break-down product (ortho-toluidine). The cyanosis appears more serious than it really is. Only 15% of the hemoglobin may be involved. The treatment is oxygen.

References

The Mercedes-Benz 280
4 wheel disc brakes, radial tires, roof roll-bar. A monument to sanity in the fine car field.

ISNOR MOTORS LTD.
1743 Brunswick Street,
Halifax, N.S.
429-2300
Prescription for Investment...

ECSL Debentures.

10%* interest, administered annually, over a 5-year term of treatment.

Consult your ECSL Investment/Savings Specialist for sound advice on healthy money matters.

*Subject to change, as are most things.

THE
EASTERN CANADA
SAVINGS AND LOAN COMPANY
Established 1887
Federally Incorporated and Supervised
Member Canada Deposit Insurance Corporation

1819 Granville Street, Halifax 422-1461
Starlite Mall,
Bayers Road Shopping Centre 454-9359
140 Portland Street, Dartmouth 469-7850
373 Main Street, Kentville 678-7397

GUIDELINES FOR AUTHORS

Reference to these guidelines and recent issues of the Bulletin will help authors in preparation of their papers. Send the original typed copy to the Editor and keep a carbon copy.

The entire manuscript (including references and tables) should be typed double-spaced, with a generous margin on the left, on only one side of the pages. Do not underline unless the type is to be set in italics. Standard abbreviations (e.g., hr, mg, ml) are acceptable without definition; less-common abbreviations should be written in full the first time they are used. Give generic as well as proprietary names and the manufacturer's name for drugs.

References. Identify references by numbers within the text, and list them in numerical order on a separate sheet (see (f)).

Figures. Provide an unmounted glossy print of each, clearly marked on the back with a SOFT marker, indicating top, figure no., and author's name. Show scale when relevant. Do not write legends on them (see (h)).

The usual framework of a paper is as given in (a) to (h) below, starting each section on a new page and numbering pages consecutively to the end of (h).

a) Front page, showing title, author(s) and degrees, whether the author is in family practice or the institution where the work was done, and address for correspondence.

b) Brief summary.

c) Introduction.

d) Materials and methods, then Results; or Case report.

e) Discussion.


Tables (each, including heading and footnotes, on a separate page).

h) Figure legends (all listed on one page); state magnification of photomicrographs.
Malignant Lumps in the Neck*
(A Five Year Review in Nova Scotia)
M. Yousuf,** M.D. and G. M. Novotny,*** M.D.,
Halifax, N.S.

It is generally accepted that metastatic carcinoma in the neck nodes comprises the most prevalent source of a malignant cervical mass. The primary site, in most cases, is in the head and neck region. It is also agreed that primary thyroid cancer is the most frequent single source of malignancy in the neck.

Incidence

To assess the experience with malignant neck masses a survey of 130 admission records was done on patients who were followed in the Nova Scotia Tumour Clinic in the period from 1968-1972 inclusive. We did not include cases who presented with masses in the supra clavicular region representing metastatic nodal deposits from primary sites below the clavicle. Primary lymphoreticular tumours were also excluded.

Of 130 patients in this survey, 122 presented with metastatic cervical node deposits from primary carcinomas in the head and neck. In comparison, only 24 patients had a primary malignancy in the cervical region. Most of these latter cases also had metastatic cervical nodes at the time of initial presentation.

The primary sites in the head and neck region for the metastatic cervical lumps are shown in Table I. Majority of these metastases originated from the oral cavity, accounting for 74 cases, followed by hypopharynx and thyroid gland. Tonsillar fossa was the commonest individual primary site followed closely by piriform sinus, inferior alveolus, floor of the mouth, posterior third of the tongue, anterior two thirds of the tongue, and thyroid gland.

Of all the primary malignant tumours appearing as neck masses, thyroid neoplasms were the commonest, accounting for 15 cases, 7 of which presented with simultaneous cervical nodal metastatic deposits. (Table II)

We were particularly interested in the records of ten patients who came with metastatic neck masses from so-called cryptic primary sites in the head and neck region. This represents about 8% in this series. In all, except one, of these cases the primary source of carcinoma was subsequently discovered either on thorough follow up examination or after histological examination of the excised surgical specimen in case of thyroid tumours. The distribution of these primary sites is shown in Table III. Seventy per cent of these resided

<table>
<thead>
<tr>
<th>TABLE I</th>
<th>Distribution of head and neck primary lesions metastasizing to cervical lymph nodes</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOTAL: 122</td>
<td></td>
</tr>
<tr>
<td>A. Oral Cavity</td>
<td></td>
</tr>
<tr>
<td>Upper lip</td>
<td>0</td>
</tr>
<tr>
<td>Lower lip</td>
<td>6</td>
</tr>
<tr>
<td>Buccal mucosa</td>
<td>2</td>
</tr>
<tr>
<td>Superior alveolus</td>
<td>2</td>
</tr>
<tr>
<td>Inferior alveolus</td>
<td>11</td>
</tr>
<tr>
<td>Floor of mouth</td>
<td>11</td>
</tr>
<tr>
<td>Anterior 1/3 Tongue</td>
<td>10</td>
</tr>
<tr>
<td>Posterior 2/3 Tongue</td>
<td>11</td>
</tr>
<tr>
<td>(and vallecula, and lingual surface of epiglottis)</td>
<td></td>
</tr>
<tr>
<td>Tonsillar Fossa</td>
<td>15</td>
</tr>
<tr>
<td>Palate</td>
<td>4</td>
</tr>
<tr>
<td>Minor Salivary glands</td>
<td>2</td>
</tr>
<tr>
<td>B. Nasopharynx</td>
<td>4</td>
</tr>
<tr>
<td>C. Nose</td>
<td>1</td>
</tr>
<tr>
<td>D. Hypopharynx</td>
<td>14</td>
</tr>
<tr>
<td>Pinform Sinus</td>
<td>12</td>
</tr>
<tr>
<td>Post Cricoid</td>
<td>1</td>
</tr>
<tr>
<td>Posterior Pharyngeal Wall</td>
<td>1</td>
</tr>
<tr>
<td>E. Supraglottic Larynx</td>
<td>6</td>
</tr>
<tr>
<td>Laryngeal Surface of Epiglottis</td>
<td>2</td>
</tr>
<tr>
<td>False Vocal Cord and Arytenoid</td>
<td>4</td>
</tr>
<tr>
<td>F. Glottic Larynx</td>
<td>7</td>
</tr>
<tr>
<td>True Vocal Cords and Ant. Commissure</td>
<td>7</td>
</tr>
<tr>
<td>G. Subglottic Larynx</td>
<td>1</td>
</tr>
<tr>
<td>H. Thyroid</td>
<td>10</td>
</tr>
<tr>
<td>F. Major Salivary Glands</td>
<td>5</td>
</tr>
<tr>
<td>Parotid</td>
<td>3</td>
</tr>
<tr>
<td>Submaxillary</td>
<td>2</td>
</tr>
</tbody>
</table>

| TABLE II | Distribution of primary malignant tumours in the neck |
| TOTAL: 24 |
| A. Thyroid | 15 |
| B. Parotid gland | 4 |
| C. Submaxillary gland | 3 |
| D. Miscellaneous | 2 |
| 1) Embryonic mesenchymal | 1 |
| 2) Malignant Thymoma | 1 |

*From the Department of Otolaryngology, Dalhousie University, Halifax, N.S.
**Teaching Fellow, Department of Otolaryngology, Dalhousie University.
***Professor and Head, Department of Otolaryngology, Dalhousie University.
in the oropharynx, hypopharynx and nasopharynx, and the remaining 30% in the thyroid gland.

One patient also included in the above table presented with metastatic squamous cell carcinoma involving cervical lymph nodes, but he died during the initial hospital admission. The primary site in this case was strongly suspected to be in the nasopharynx but it was not confirmed either ante or post-mortem.

### TABLE III

Distribution of "Cryptic" Primary Sites.

<table>
<thead>
<tr>
<th>Primary Site</th>
<th>A. Oropharynx</th>
<th>Tonsillar fossa</th>
<th>Base of Tongue</th>
<th>B. Hypopharynx</th>
<th>Post-cricoid</th>
<th>Piriform Sinus</th>
<th>C. Nasopharynx</th>
<th>D. Thyroid</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOTAL</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>3</td>
</tr>
</tbody>
</table>

### Management of cryptic primary head and neck carcinoma metastatic to cervical lymph nodes

Regarding the management of patients presenting with metastatic squamous cell carcinoma involving the cervical lymph nodes, the primary site of which is not confirmed, the opinion is divided whether to apply surgery or radiotherapy as the primary modality of treatment. The overall prognosis in these cases is uniformly grave but the proponents of both schools of thought claim to have achieved equally good results with their form of therapy.

In our survey, eight of the ten patients reviewed received full course cobalt therapy both to the primary and metastatic lesion, in dosage ranging from 5500 to 6000 rads. Two of these eight patients subsequently underwent radical neck dissection for persistence of metastatic cervical mass and one of these 8 patients received methotrexate therapy for palliation because of recurrent disease following cobalt therapy.

One patient, out of the ten cited, was treated by surgery alone (total thyroidectomy and radical neck dissection) for metastatic papillary carcinoma of the thyroid gland. The remaining one patient, who was suspected to have the primary lesion in the base of the tongue, was treated by chemotheraphy alone, using Bleomycin initially, followed by Methotrexate which was continued until his death. (Table IV).

### Results of Therapy: Comments

The results of therapy in our survey are summarized in Tables V and VI. Two of the ten patients survived for four years or longer. One of these had presented with metastatic neck mass from a primary lesion in the tonsilar fossa, treated primarily with full course cobalt therapy with good tumour response and subsequently using palliative Methotrexate therapy for recurrence. The second patient, who is still alive, arrived with a neck mass metastatic from a small primary focus in the piriform sinus. He was treated with full course cobalt therapy followed by radical neck dissection.

One patient, who was found to have the primary lesion in the posterior third of the tongue, was treated with chemotherapy alone (Bleomycin and Methotrexate). There was minimal tumour regression but the patient lived for 40 months since the initial appearance of the neck mass.

Two patients with metastatic neck masses from papillary carcinoma of the thyroid are still alive for over three years since initial presentation. One of them received radiation therapy alone, while the other was treated by total thyroidectomy and radical neck dissection.

The third patient with the primary site in the thyroid gland (anaplastic carcinoma) was treated with cobalt therapy alone. There was minimal tumour response and the patient died 27 months later of asphyxia and inanition.

### TABLE IV

Treatment used in patients who initially presented with metastatic neck masses from cryptic primary carcinoma in the head and neck region.

<table>
<thead>
<tr>
<th>Primary Site</th>
<th>Full Course Radiotherapy</th>
<th>Surgery alone</th>
<th>Full Course Radiotherapy &amp; Surgery (Radical Neck Dissection)</th>
<th>Full Course Radiotherapy &amp; Chemotherapy</th>
<th>Chemotherapy alone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tonsillar fossa</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Base of Tongue</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post-cricoid</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Piriform Sinus</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasopharynx</td>
<td>2</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thyroid</td>
<td>2</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### TABLE V

Results of Therapy

<table>
<thead>
<tr>
<th>Duration of Survival</th>
<th>Radiotherapy alone</th>
<th>Surgery alone</th>
<th>Radiotherapy &amp; Surgery</th>
<th>Radiotherapy &amp; Chemotherapy</th>
<th>Chemotherapy alone</th>
<th>Total No. of Survivals</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 yrs. or more</td>
<td>1*</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>3-4 years</td>
<td>1*</td>
<td>1*</td>
<td></td>
<td></td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>2-3 years</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>1-2 years</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>Less than 1 year</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td>2</td>
</tr>
</tbody>
</table>

*Patient alive at the time of the survey.

### TABLE VI

Patient survival as related to the site of cryptic primary lesion.

<table>
<thead>
<tr>
<th>Primary Site</th>
<th>Total no. of Cases</th>
<th>4 yrs. or more</th>
<th>3-4 years</th>
<th>2-3 years</th>
<th>1-2 years</th>
<th>Less than 1 year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tonsillar fossa</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Base of Tongue</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Piriform Sinus</td>
<td>1</td>
<td>1*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post-cricoid</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasopharynx</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Thyroid</td>
<td>3</td>
<td>2*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Patients alive at the time of the survey.

Two patients lived for 15 months each. One was detected to have the primary cancer in the nasopharynx and the other in the post-cricoid region. Both patients were treated with radiotherapy alone.

One patient with suspected primary lesion in the nasopharynx metastatic to the neck was started on radiotherapy but he died during the course of the treatment, having lived for two and a half months since the neck mass was first noted.

From our survey it is evident that excluding the two cases of papillary carcinoma of the thyroid gland metastatic to the cervical lymph nodes, which is known to be associated with long survival, three of our remaining eight patients have survived for more than three years, carrying a crude survival rate of 38%. Metastatic disease from the nasopharynx carried the worst prognosis in our review and only one patient out of three survived for 15 months.

In comparison Marchetta et al. reported a four year cure rate of 39% in 33 such cases, where radiation therapy alone was used.

Barrie et al., however, reviewed a series of 123 such patients and reported an absolute survival rate of 31% for 3 years, 25% for 5 years, 16% for ten years and 13% for 15 years. In their series, the metastatic neck disease was always treated by surgery (radical neck dissection).

**SUMMARY**

Metastatic nodal deposits in the neck, from head and neck primary sites, are the commonest source of malignant neck masses. Eight per cent of these masses in our survey initially
presented with cryptic primary sites which were eventually detected to be residing in the oropharynx, hypopharynx, nasopharynx or the thyroid gland. Radiotherapy was used as the primary modality of treatment in majority of these cases, with surgery reserved for the residual cervical disease and chemotherapy for palliation. Excluding thyroid papillary carcinoma metastatic to the cervical lymph nodes, 38% of the cases in this series have survived for more than three years. When nasopharynx was the site of the primary cancer, the outlook was uniformly grave.

Acknowledgement
We wish to thank all members of the Nova Scotia tumour clinic who made the patient records available to us for making this study possible.

References

Physician Self-Assessment

Lea C. Steeves, M.D.,
Halifax, N.S.

The following questions have been submitted by the Division of Continuing Medical Education, Dalhousie University, and are reprinted from The American College of Physicians Medical Knowledge Self-Assessment Test No. 1 with the permission of Dr. E. C. Rosenow, Executive Vice-President.

It is our hope that stimulated by these small samplings of self-assessment presented you will wish to purchase a full programme.

DIRECTIONS: Each of the questions or incomplete statements below is followed by five suggested answers or completions. Select the ONE that is BEST in each case.

A 26-year-old Negro man complains of arthralgia and mild dyspnea on exertion. Physical examination shows hepatosplenomegaly, generalized lymphadenopathy, and bilateral iritis. Roentgenogram of the chest shows bilateral, symmetrical hilar adenopathy.

4. Which of the following is the most likely diagnosis?
   (a) Rheumatic fever
   (b) Rheumatoid arthritis
   (c) Sarcoidosis
   (d) Tuberculosis
   (e) Hodgkin's disease

5. Which of the following abnormal laboratory findings is most likely to be present?
   (a) High serum calcium
   (b) Low serum calcium
   (c) High serum magnesium
   (d) High serum phosphorus
   (e) Low serum phosphorus

6. Which of the following tests would most likely be positive?
   (a) Tuberculin skin test (PPD No. 2)
   (b) Alcohol tolerance test
   (c) Latex fixation test
   (d) Elevated antistreptolysin O titer
   (e) Kveim test

(Please turn to page 31 for answers)
Each new generation's traditions depend on the quality of the last generation's standards.

Donnatal

After almost two generations, still the most widely prescribed antispasmodic/sedative in Canada.

For complete prescribing information, consult product literature or the Compendium.

A H ROBINS
A. H. Robins Company of Canada, Ltd., Montreal, Quebec
Dysplastic Lesions of the Uterine Cervix

Ian Maxwell,* M.B., Ch.B., FRCP(C),
Halifax, N.S.

Between benign physiological changes of metaplasia and hyperplasia on the one hand and frank malignancy on the other, there is no simple, sharp dividing line, but rather a no-man’s-land composed of an infinite gradation of aberrations in cellular growth patterns. These cellular abnormalities are termed dysplasias.

At one end the cytopathologist may be able, with a fair degree of confidence, to say "... almost certainly not malignant" and at the other "... almost certainly malignant" but in between he must weigh up the odds of these two probabilities, 10:1, 8:5, 1:3, and so forth. If there is not to be a communications gap, he must be able to pass this information on to the clinician. This was the intent of the original numerical classification introduced by George Papanicolaou almost 30 years ago.

Since that time increased experience with the technique and greatly increased knowledge of the significance of the various criteria described by Papanicolaou have resulted in considerable modification of the usual numbering scheme. In a nationwide survey, which I conducted some three years ago, 75% of the laboratories no longer employed it.

In Nova Scotia the situation was particularly unfortunate. In one large centre, a high proportion of smears, almost 80%, were reported as Class II, that is "Benign changes, not suggestive of malignancy", which added not a whit to the diagnostic value of the test, and many of the remainder had been consigned to a grabbag, peculiar to Nova Scotia, known as "class deferred".

DEFER, according to the dictionary, means "to adjourn, stave off, to delay to act, retard, postpone, to waste time by delay, to put off, procrastinate," and that is hardly the response which would be helpful to the concerned clinician or even one to be expected from the omnipresent pathologist. Clearly we in Nova Scotia were at variance with the rest of the world and changes were long overdue.

DYSKARYOSES

But what to recommend? Cellular abnormalities lying in that borderland of atypia which bridges the gap between truly benign and frankly malignant were given the name dyskaryosis by Papanicolaou, from dys — abnormal, or disordered and karyos — a nut or nucleus. A dyskaryotic cell, then by definition is one which has a disorderly nucleus. Papanicolaou recognized various gradations of this condition from early changes in which the nucleus was simply enlarged and rather hyperchromatic to late or advanced dyskaryosis in which the nuclear changes were those indistinguishable from carcinoma. By and large, however, according to Papanicolaou, the cytoplasm of the dyskaryotic cells was normal enabling their differentiation from true cancer cells.

The situation proved, however, to be not quite so simple. It was soon realized that various gradations of parallel immaturity of the cytoplasm could be recognized. To describe these Papanicolaou used a comparison based on the cell they resembled most closely. In squamous epithelium the most mature cells lie on the surface until desquamated whereas the least mature are situated in the depths. To indicate increasing degrees of immaturity, and so of malignant propensity, Papanicolaou spoke of superficial dyskaryotic cells, intermediate dyskaryotic cells, and parabasal dyskaryotic cells to indicate the cytoplasmic type i.e. hypermature, immature, etc. Unfortunately this nomenclature was widely misinterpreted as representing a source oriented classification so that a superficial dyskaryotic cell was automatically considered to have originated superficially and a parabasal one, deeply. Although this might well sometimes have been the case, the malignant potentials of the reverse, i.e. a deeply arising so-called "superficial" dyskaryotic cell or a superficially placed "parabasal" one were infinitely more ominous and the term dyskeratosis, or abnormal keratin production, was soon adopted to indicate cytoplasmic abnormalities.

DYSKERATOSES

Regrettably, even the term dyskeratosis is fraught with problems. Not only, as with dyskaryosis, is it not part of the normal vocabulary of the clinician, and its import therefore possibly not quite clear to him, but also it has, quite properly from the semantic point of view, been applied to two completely different types of pathologic change. On one hand there are the benign dyskeratoses typified by the swollen, brightly eosinophilic cells of molluscum contagiosum or the corps ronds of Darier’s disease, both of them packed with viral inclusion bodies; these conditions do not lead to any increased likelihood of subsequent carcinoma. The second group represent the malignant dyskeratoses seen for example in xeroderma pigmentosum, leukoplakia, solar keratosis, senile keratosis and the like, which may sometimes be indistinguishable from true carcinoma-in-situ and which unquestionably carry a greatly increased incidence of subsequent carcinoma developing in the same area. Some textbooks place erythroplasia of Queyrat and Bowen’s...

*Assistant Professor, Dept. of Pathology, Dalhousie University and Associate Director of Laboratories, Halifax Infirmary, Halifax, N.S.
disease in this category whereas others regard them as actual intraepithelial carcinomas.

Both varieties of dyskeratosis are represented in exfoliative cytology; the benign one in infections of various sorts, and the malignant variety, either arising de novo, preceding the development of carcinoma-in-situ by a variable period or deriving from the epithelium adjacent to in-situ or microinvasive carcinomas; representing prodromal evidence of the spread of the malignant process. Radiation changes in benign epithelium often show a similar picture. Nor is it by any means always possible to say where dyskaryosis and dyskeratosis end and anaplasia, that is reversion to a primitive undifferentiated state begins.

ANAPLASIAS

Even the word "anaplasia" is open to some misunderstanding. "The term anaplasia (distinct from anaplastic carcinoma) has no uniform interpretation. It is used by some to mean a primitive cell by others to indicate neoplastic character of the cell or lack of organization in a tumor. Popular usage has conferred a more specific meaning; that individual neoplastic cells . . . have not replaced sufficient normal tissue to be regarded as an established progressive growth, a cancer." Whether or not one agrees with this summation, any classification which is not necessarily indicate that the patient is about to develop invasive carcinoma and it is probably true that most clinicians now accept this fact. Even more so is it the case with dysplasia; in fact the natural history of mild dysplasia is almost invariably one of regression. This does not, however, hold true for either moderate or for severe dysplasia which if it is not progress to intraepithelial carcinoma or even direct to invasive carcinoma without ever passing through the stage of carcinoma-in-situ. Careful cytologic follow-up of all patients with any report of dysplasia particularly of moderate or severe degree is therefore mandatory.

CLINICAL SIGNIFICANCE

For over 20 years pathologists have recognized that discovery of carcinoma-in-situ of the cervix does not necessarily indicate that the patient is about to develop invasive carcinoma and it is probably true that most clinicians now accept this fact. Even more so is it the case with dysplasia; in fact the natural history of mild dysplasia is almost invariably one of regression. This does not, however, hold true for either moderate or for severe dysplasia which if it is not progress to intraepithelial carcinoma or even direct to invasive carcinoma without ever passing through the stage of carcinoma-in-situ. Careful cytologic follow-up of all patients with any report of dysplasia particularly of moderate or severe degree is therefore mandatory.

It is fairly generally agreed that a grading of mild dysplasia would imply "Not malignant and probably not even pre-malignant. If there is infection, bring it under control and then send another smear. Check at least once a year unless you consistently receive normal reports in the future."

On the other hand, a grading of moderate dysplasia would mean "I do not think that this is malignant, but I could just possibly be mistaken particularly if this has been a poorly taken specimen or if I have been fooled into overevaluating the part played by the infection which is also present in this slide. Anyway, infection or not, this patient is definitely a person at risk and she has at least a 50:50 chance of developing actual carcinoma-in-situ or invasive carcinoma within the next 10 years. Don't panic but you are strongly advised to clear up any infection and then send another slide, say in a month or two. If it clears up then an annual slide should suffice, but if you do not get a normal report then follow her every three to four months and if the condition does not improve, conization of the cervix should seriously be considered."

A grading of severe dysplasia would imply, and I would so indicate myself within the constraints of the form, "This is definitely a pre-malignant condition. I do not think it represents an actual carcinoma-in-situ but I regard it as the next stage to that condition. In the long run I would reckon that she stands an 80% chance of developing either intraepithelial or invasive carcinoma within the next five to ten years, perhaps sooner. On the other hand, the whole condition may clear up but I think this unlikely. If she wishes
to have a family, she may want to carry on for awhile but if so watch her very closely indeed and carry out conization of the cervix before she becomes pregnant. Any infection present should be brought under control without delay and a repeat slide submitted. If you persistently get reports of this grade without any apparent remission within the next six months, then carry out a cone biopsy because there may be an occult carcinoma-in-situ close by."

This is a lot of mileage to expect from a simple, three category check-off form and a number of cytology laboratories eschew such forms and employ a freestyle report on a blank page after the fashion of the usual tissue report. There are, however, many advantages to be gained by the use of a standardized layout and graded classification of changes, provided the meaning of the shorthand is understood both by the doctor issuing the report and by the one who receives it. Fortunately a telephone is always handy to clear up any misunderstanding.

References

———

LEASE / SALE

HALIFAX

Ideal small modern professional building suitable for doctors offices or clinic.
Downtown Spring Garden Road area.
3,000 sq. ft./Parking/Landscaped.
Telephone 422-9322 from 9 to 5 or 434-5594 after 6.
Excellent potential.

ASSOCIATE WANTED to join three family physicians in rapidly expanding practice in suburb of Halifax. Drs. Fraser, Guest and Childs, Sunnyside Mall, Bedford, N.S. (902) 835-3361.

LOCUM REQUIRED for two months commencing 1st August 1976 for solo general practice (No obs). Excellent duty rota terms negotiable. Applicant must have Nova Scotia licence. Apply Dr. M. F. Husain, Box 128, Amherst, N.S. B4H 3Y6 (902) 667-2331.

———

FEBRUARY, 1976
Retirement investment shouldn’t be a shell game.
Maritime Life lets you choose all three ways to security with one premium payment.

In today’s financial climate your investment plans need to be flexible enough to adjust to changing conditions.

So what do you look for?
Well, first don’t be taken in by a lot of smooth talk about tax savings and future security. Every registered retirement savings plan will give you that.

No, what you should look for is flexibility. Look for a plan that’s flexible enough to meet your specific needs both today and in the future.

And that’s where Maritime Life Assurance comes in. Of all the insurance companies Maritime Life doesn’t lock you into a single investment format. In fact, our new Triflex Annuity Plan not only allows you your choice of three excellent investment vehicles, it also allows you to split your premium into the three funds in the proportions you choose.

So let’s take a look at the three options.

Guaranteed Portion
Safe as the proverbial church. The percent of interest paid on your premium payment is fully guaranteed for five year terms. At the end of any term you can reinvest at the new guaranteed rate or move your money to another fund.

Property Fund
Premiums are invested in mortgages and property to provide a hedge against inflation while allowing you to benefit from the present real estate boom.

Growth Fund
An excellent investment in equities consisting of units of the Maritime Life Growth Fund. Although the exact results will depend entirely on the economy and the stock market, the investment policy of the fund is to achieve maximum long-term growth.

There are a lot of other big plusses with the Triflex Annuity Plan as well.

Like the fact that immediate cash values are available from the moment you enter the plan.

Like the flexible premium payment plans that don’t tie you down to a contractual payment plan. Subject to minimums, payments can be made at any time.

Like the fact you can adjust your investment goals on any fifth policy anniversary and alter the proportions of your plan between the three funds.

If you’re interested, just fill out the coupon below. We’ll see that you receive full, detailed information on our new Triflex Annuity Plan.

The Maritime Life Assurance Company
P.O. Box 1030
Halifax, Nova Scotia B3J 2X5

Please send me more information on the new Triflex Annuity Plan.

Name
Address
City/Town
Province
Postal Code
New Drug Evaluations

SILVER SULFADIAZINE
(FLAMAZINE® - SMITH & NEHPHW LTD)

Approved Indications
Topical therapy for the adjunctive treatment and prevention of infection in severe burns.

Pharmacology/Mechanism of Action
Silver sulfadiazine is a broad-spectrum antibacterial agent. It appears to inhibit DNA, RNA, and protein synthesis by binding to bacterial cell membranes and, to a lesser extent, the bacterial cell wall. The silver has also been shown to bind to the bacterial DNA. Unlike other sulfonamides, the action is bactericidal and is not inactivated by wound exudate or para-aminobenzoic acid.

Biopharmaceutics
Relatively insoluble, silver sulfadiazine acts as a drug depot in the epithelium. The silver reacts extremely slowly with chloride, sulfhydryl compounds and protein in the wound to liberate sulfadiazine. The silver remains in the exudate while the sulfadiazine is absorbed, usually below 10%, yielding blood levels in the 3-5 mg% range. About 50% protein bound, the absorbed drug is rapidly cleared by the kidneys (15-40% inactive acetylated metabolite, 60-85% unchanged), and is actively reabsorbed (70%) by the renal tubules. Impaired hepatic and/or renal function may result in increased systemic blood levels, especially following prolonged treatment of extensive burns. Sulfadiazine crosses the placenta and appears in the milk.

Toxicology
Topically applied, silver sulfadiazine has shown little evidence of toxicity following acute and chronic applications. Overdosage, either topically or orally, has not been reported. Animal and human studies have failed to demonstrate teratogenic effects.

Summary of Clinical Trial Results
Clinically attainable concentrations of silver sulfadiazine have been shown to inhibit the growth of various strains of Enterobacter, Klebsiella, Escherichia coli, Proteus, Pseudomonas, Staphylococcus, Streptococcus, and some strains of Candida albicans. The development of bacterial resistance and/or superinfection has been very low. Studies have shown silver sulfadiazine to be as effective as silver nitrate or mafenide, but without the complications of staining, painful application, or electrolyte and acid-base disturbances. Because of decreased eschar autolysis, treatment should be combined with daily hydrotherapy and debridement.

Side Effects/Adverse Drug Reactions (ADR)
This compound is generally well tolerated. Less than 3% of patients experience local reactions, such as rash, pruritus, or a burning sensation. Sensitization has been reported at less than 0.25%, although cross-sensitivity with other sulfonamides is a possibility. Since significant amounts of the drug may be absorbed following prolonged treatment of extensive burns, all the adverse reactions attributable to systemic sulfonamide therapy are possible.

Drug Interactions/Laboratory Modifications
No consistent, clinically significant interactions have been reported.

Evaluation of Therapy
In favorable cases, epithelialization of second-degree burns is apparent after about 10 days. Treatment should be continued until satisfactory healing has occurred or until the burned site is ready for grafting.

Dosage/Administration
Following cleansing and debriding of the wound, the drug should be applied topically with a sterile gloved hand or spatula once or twice daily to a 1-5 mm thickness. More frequent applications may be made if required, and the wound may be dressed or left open. Concomitant daily hydrotherapy and debridement are recommended.

Application is not recommended to pregnant women at term nor to premature/newborn infants.

How Supplied/Drug Identification
Available for hospital use only. 1% w/w micronized silver sulfadiazine in a topical, water-miscible cream base.

Cost: $20.00 per 500 Gm wholesale.

References

*Detailed bibliography available from Dr. W. A. Parker, Dalhousie University College of Pharmacy, Halifax, N.S.
Correspondence

To the Editor:

As a regular reader of the publications of the provincial Divisions of the C.M.A., I nominate the Nova Scotia Medical Bulletin as the best. Although long delayed in the mail, your August-October issue 1975 is a case in point. The writings of the late Jim Reid set the tone and one does not have to be a Senior Citizen to appreciate the merits of the symposium on geriatrics.

Back injuries, medical women, smallpox, obituaries, Around the Willow Tree, gardening — I read them all with interest. Without offence to Dr. McQueen, a metric illiterate must confess that the S.I. Units was difficult to comprehend and I'll reserve for future perusal the Constitution and By-Laws of the Society.

Permit me to congratulate you on the excellence of your Bulletin.

Yours,
A.D. Kelly, O.C., M.B., D.Sc., L.L.D.
5 Edmund Gate
Toronto, Canada
M4V 2M1

NEW MEMBERS

The Physicians listed below have joined The Medical Society of Nova Scotia between November 1, 1975 and January 31, 1976. A most cordial welcome is extended by the Society.

Dr. Ian H. Anderson
Digby, N.S.

Dr. John M. Archibald
Sydney, N.S.

Dr. L. William Caines
Halifax, N.S.

Dr. Allan D. Cohen
Halifax, N.S.

Dr. Ivan A. A. DeCoutere
Dartmouth, N.S.

Dr. Roland J. Genge
Baddeck, N.S.

Dr. J. David Gordon
Digby, N.S.

Dr. John A. Hynes
Kentville, N.S.

Dr. Peter H. Jeffrey
Shelburne, N.S.

Dr. Kamla Kishan
New Minas, N.S.

Dr. Liam L. McKeough
Sydney, N.S.

Dr. Christopher B. MacNamara
Cheticamp, N.S.

Dr. Annada Pandey
Sydney, N.S.

Dr. P. Michael Reardon
Halifax, N.S.

Dr. Michael D. Riding
Halifax, N.S.

Dr. Thomas W. Shaw
Kentville, N.S.

Dr. Wing-Hei Tam
Truro, N.S.

Dr. Robert J. Wedel
Halifax, N.S.

Dr. Peter R. White
Sydney, N.S.

When you’re ready to set up practice, we’re ready to help.

Bank of Montreal. We’ve been helping doctors and dentists longer than any other Canadian bank. We’ve got plans designed to meet your particular needs.

Operating funds, term loans and mortgages (business or personal). We can also arrange your car or equipment leasing.

We mean it when we say

Just look for the shingle.
The First Canadian Bank
Bank of Montreal

NO SMOKING

Once again there is a tip-in which may be easily removed for use as a poster in a place of your choice.

The Society’s Drug and Alcohol Abuse Committee appreciates your co-operation in the Medical Profession’s anti-smoking campaign.
NEW APPOINTMENTS AND SERVICES*
Izaak Walton Killam Hospital for Children

Early in 1976 a new service to family physicians will be inaugurated as part of the Regional Pediatric Services of the Izaak Walton Killam Hospital for Children. This will consist of a monthly newsletter which will be mailed without charge to every family physician in the province. The newsletter is designed to be of immediate practical value to all physicians who care for infants and children. The entire publication will be readable in a matter of minutes, and will include such features as:

1) Practical guides to appropriate uses of medication in children.
2) Common misconceptions in pediatric care.
3) Advances in pediatrics that are of practical value to the family physician.
4) A “Question and Answer” section in which questions from community physicians on pediatric topics will be answered.
5) News and announcements: Information concerning new services available to children, new appointments, etc., with emphasis on services available outside the Halifax-Dartmouth area.

Regional Pediatric Care Program

This unique, provincially-sponsored program is designed to improve both preventive and therapeutic health care of children throughout Nova Scotia within their own communities. Coordinator of the program is Sister Nuala Kenny, M.D., and the project has received the enthusiastic endorsement of The Medical Society of Nova Scotia, as well as that of the Nova Scotia College of Family Practice and the Nova Scotia Council of Health.

The program permits a highly-trained pediatrician (Dr. Kenny) to visit any community or region of the province that officially requests her services, either through the local branch of the Society or the community hospital. Dr. Kenny will spend significant periods of time, e.g. one month or longer, working with health care professionals to improve the quality of care for infants and children in the community.

Several features of the program deserve emphasis: First, participation is only at the request of the physicians and/or hospital of the community. Second, there is no charge for any of the services. Third, it is considered essential that the program should help strengthen or establish only those services that can continue to be sustained by the community itself.

Services offered include audits of pediatric hospital practices; assessment of pediatric needs of the community; working with physicians and public health nurses to improve immunization practices and other preventive services such as pre-school screening for vision and hearing defects; pediatric consultation with individual physicians in their offices or in hospital; substitution for local pediatricians who wish to spend brief periods in post-graduate study; the improvement of care for children with complex or chronic illness within their own communities; and improvement of liaison and collaboration with the staff and services of the Izaak Walton Killam Hospital for Children. A major objective is to reduce unnecessary travel by patient to Halifax, and thereby to cut financial and emotional costs to many families.

Ultimately, it is hoped that the program will encourage highly qualified pediatric consultants to settle in the many areas of the province which currently offer no such consultant personnel, but where the population base is more than adequate to support such services.

Although the program has only begun, the response of physicians and hospitals throughout the province has been overwhelmingly enthusiastic. Already, Dr. Kenny has been invited to visit Bridgewater, Liverpool, Digby, the Annapolis Valley, Yarmouth and New Glasgow and has made preliminary visits to several of these communities. She will spend the month of November in the New Glasgow area.

New Appointments

Dr. Barry J. Bergen has been appointed Lecturer in the Department of Pediatrics and a member of the full-time Active Medical Staff of the Izaak Walton Killam Hospital for Children.

A Manitoban by birth, Dr. Bergen is a pediatric neurologist who graduated in Medicine from the University of Manitoba in 1967. Following internship and pediatric residency in Minnesota (Mayo Clinic) and the Children's Hospital in Winnipeg, he spent the period 1972-75 training in pediatric neurology at the University of Minnesota. In addition to his experience in pediatric neurology, Dr. Bergen is also trained in electroencephalography and electromyography.

Dr. Bergen's appointment represents part of a program to strengthen both teaching and service in pediatric neurology in the Maritime region. Until his appointment, Dr. John Tibbles had been the sole pediatric neurologist in the three Maritime provinces.

In January, 1976, Drs. Tibbles and Bergen will be joined by another new appointee in pediatric neurology, Dr. Jean Gibson. Dr. Gibson is a Dalhousie graduate, fully trained in both pediatrics and neurology through both the Dalhousie and McGill programs. Under her guidance it is planned to establish a new Child Development Clinic at the Izaak Walton Killam Hospital for Children. The purpose of this Clinic is to institute a highly efficient system for the rapid investigation of

*From the Department of Pediatrics, Dalhousie University, Halifax, N.S.
children with developmental delays, leading to a comprehensive management plan which can be carried on as much as possible within the child’s own community. The clinic will bring together specialists in pediatrics, neurology, genetics, psychology, education, physio- and occupational therapy, so that families will have the opportunity of meeting all the appropriate consultants at one time and so that a system of comprehensive management and follow-up of such children can be maintained.

Dr. Maurice A. Nanton, a pediatric cardiologist, has joined the Department of Pediatrics and the full-time staff of the Izaak Walton Killam Hospital for Children. Dr. Nanton is a 1964 medical graduate of Leeds University. His early training in England was chiefly in Internal Medicine and Cardiology. He came to Canada in 1973 and became a Research Fellow in Cardiology at the Hospital for Sick Children, Toronto, a post he held for two years until moving to Halifax.

Dr. Nanton joins Dr. Douglas L. Roy in the Department of Cardiology at the Izaak Walton Killam Hospital for Children, and brings with him an extensive experience in clinical cardiology, cardiac catheterization and echocardiography.

Dr. Sonia Salisbury joined the Department of Pediatrics with the rank of Assistant Professor in October, 1975, as pediatric endocrinologist at the Izaak Walton Killam Hospital for Children. She holds a joint appointment in the Department of Medicine.

Dr. Salisbury graduated in medicine from McGill in 1959 with a distinguished academic record. She held a Medical Research Council Fellowship from 1964-67 and did graduate training in endocrinology at The Middlesex Hospital, London; and New England Medical Center Hospitals, Boston; The Beth Israel Hospital, Boston; and the Royal Victoria Hospital in Montreal. She is a Canadian authority in the field of thyroid disease, and has authored numerous publications on this subject.

In addition to her undergraduate and postgraduate teaching responsibilities in endocrinology, Dr. Salisbury will be supervising the Endocrine Clinic and the Clinical Investigation Unit at the I.W.K. Hospital for Children. She will also be investigating the feasibility of establishing a newborn screening program for congenital hypothyroidism for all infants born in the province.

The J. J. Carroll House for Senior Citizens has been opened in Antigonish, N.S. It has been named to honor Dr. James J. Carroll (Dal./24). He has practised in Antigonish since 1930. Dr. Carroll has also been honored by his fellow practitioners in 1972 with an Honorary membership in The Medical Society of Nova Scotia. He was awarded an honorary doctorate of laws by St. Francis Xavier University in 1973 and was named the Senior Doctor of the Year in Nova Scotia by the Canadian Medical Association in 1973.

Tribute was paid to Dr. Arthur Hines on the occasion of his 84th birthday on Nov. 1, 1975 by the community of Cheverie, N.S., and his former patients. As well as his dedicated service in medicine he took an active interest in community affairs. According to his many friends, he made the term “Country Doctor” come alive with true meaning.

Dr. R. Wayne Putman (Dal./69) has been named Assistant Director of the Division of Continuing Medical Education, Faculty of Medicine, Dalhousie University. A native of Truro, N.S., he practiced in Fredericton, N.B., for six years before accepting this post and a lectureship with the Division of Family Medicine.

*As this issue goes to press, we have learned that Dr. Hines passed away on January 27, 1976. Our sympathy is extended to his family.*

**Physician Self-Assessment**

| Question No. 4 | Correct Answer C |
| Question No. 5 | Correct Answer A |
| Question No. 6 | Correct Answer E |

**ADVERTISERS’ INDEX**

| Bank of Montreal | 29 |
| C.M.A.R.S.P. and C.M.A.R.H.O.S.P. | 12,13,14 |
| Central and Nova Scotia Trust | IBC |
| Eastern Canada Savings and Loan Company | 18 |
| Health Care Services — Upjohn | OBC,26 |
| Insurance Program — M.S. of N.S. | 7,8 |
| Isnor Motors Ltd. | 17 |
| Maritime Life Insurance | 27 |
| Maritime Telegraph and Telephone Co. Ltd. | IFC |
| Medical Estate Planning Services | 31 |
| Mont Sutton | 3 |
| Robins, A.H. Company of Canada Ltd | 23 |
| Royal Trust | 26 |
| Sandoz Canada Limited | Insert, 3 |
| Classified | 26 |